642 related articles for article (PubMed ID: 32545494)
21. Molecular mechanisms of selective estrogen receptor modulator activity in human breast cancer cells: identification of novel nuclear cofactors of antiestrogen-ERα complexes by interaction proteomics.
Cirillo F; Nassa G; Tarallo R; Stellato C; De Filippo MR; Ambrosino C; Baumann M; Nyman TA; Weisz A
J Proteome Res; 2013 Jan; 12(1):421-31. PubMed ID: 23170835
[TBL] [Abstract][Full Text] [Related]
22. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
[TBL] [Abstract][Full Text] [Related]
23. ERbeta in breast cancer--onlooker, passive player, or active protector?
Fox EM; Davis RJ; Shupnik MA
Steroids; 2008 Oct; 73(11):1039-51. PubMed ID: 18501937
[TBL] [Abstract][Full Text] [Related]
24. Functional characterization of estrogen receptor subtypes, ERalpha and ERbeta, mediating vitellogenin production in the liver of rainbow trout.
Leaños-Castañeda O; Van Der Kraak G
Toxicol Appl Pharmacol; 2007 Oct; 224(2):116-25. PubMed ID: 17662327
[TBL] [Abstract][Full Text] [Related]
25. Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα
Puyang X; Furman C; Zheng GZ; Wu ZJ; Banka D; Aithal K; Agoulnik S; Bolduc DM; Buonamici S; Caleb B; Das S; Eckley S; Fekkes P; Hao MH; Hart A; Houtman R; Irwin S; Joshi JJ; Karr C; Kim A; Kumar N; Kumar P; Kuznetsov G; Lai WG; Larsen N; Mackenzie C; Martin LA; Melchers D; Moriarty A; Nguyen TV; Norris J; O'Shea M; Pancholi S; Prajapati S; Rajagopalan S; Reynolds DJ; Rimkunas V; Rioux N; Ribas R; Siu A; Sivakumar S; Subramanian V; Thomas M; Vaillancourt FH; Wang J; Wardell S; Wick MJ; Yao S; Yu L; Warmuth M; Smith PG; Zhu P; Korpal M
Cancer Discov; 2018 Sep; 8(9):1176-1193. PubMed ID: 29991605
[TBL] [Abstract][Full Text] [Related]
26. A new small molecule inhibitor of estrogen receptor alpha binding to estrogen response elements blocks estrogen-dependent growth of cancer cells.
Mao C; Patterson NM; Cherian MT; Aninye IO; Zhang C; Montoya JB; Cheng J; Putt KS; Hergenrother PJ; Wilson EM; Nardulli AM; Nordeen SK; Shapiro DJ
J Biol Chem; 2008 May; 283(19):12819-30. PubMed ID: 18337247
[TBL] [Abstract][Full Text] [Related]
27. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
[TBL] [Abstract][Full Text] [Related]
28. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
[TBL] [Abstract][Full Text] [Related]
29. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists.
Barkhem T; Carlsson B; Nilsson Y; Enmark E; Gustafsson J; Nilsson S
Mol Pharmacol; 1998 Jul; 54(1):105-12. PubMed ID: 9658195
[TBL] [Abstract][Full Text] [Related]
30. Dual functional small molecule fluorescent probes for image-guided estrogen receptor-specific targeting coupled potent antiproliferative potency for breast cancer therapy.
Yang L; Hu Z; Luo J; Tang C; Zhang S; Ning W; Dong C; Huang J; Liu X; Zhou HB
Bioorg Med Chem; 2017 Jul; 25(13):3531-3539. PubMed ID: 28506582
[TBL] [Abstract][Full Text] [Related]
31. Recent advances in peptidomimetics antagonists targeting estrogen receptor α-coactivator interaction in cancer therapy.
Qin W; Xie M; Qin X; Fang Q; Yin F; Li Z
Bioorg Med Chem Lett; 2018 Sep; 28(17):2827-2836. PubMed ID: 30025900
[TBL] [Abstract][Full Text] [Related]
32. Mutation of Leu-536 in human estrogen receptor-alpha alters the coupling between ligand binding, transcription activation, and receptor conformation.
Zhao C; Koide A; Abrams J; Deighton-Collins S; Martinez A; Schwartz JA; Koide S; Skafar DF
J Biol Chem; 2003 Jul; 278(29):27278-86. PubMed ID: 12736255
[TBL] [Abstract][Full Text] [Related]
33. Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.
Smollich M; Götte M; Fischgräbe J; Radke I; Kiesel L; Wülfing P
Anticancer Res; 2009 Jun; 29(6):2167-71. PubMed ID: 19528477
[TBL] [Abstract][Full Text] [Related]
34. A noncompetitive small molecule inhibitor of estrogen-regulated gene expression and breast cancer cell growth that enhances proteasome-dependent degradation of estrogen receptor {alpha}.
Kretzer NM; Cherian MT; Mao C; Aninye IO; Reynolds PD; Schiff R; Hergenrother PJ; Nordeen SK; Wilson EM; Shapiro DJ
J Biol Chem; 2010 Dec; 285(53):41863-73. PubMed ID: 21041310
[TBL] [Abstract][Full Text] [Related]
35. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine.
Sui M; Jiang D; Hinsch C; Fan W
Breast Cancer Res Treat; 2010 Jun; 121(2):335-45. PubMed ID: 19626437
[TBL] [Abstract][Full Text] [Related]
36. Role of SUMOylation in differential ERα transcriptional repression by tamoxifen and fulvestrant in breast cancer cells.
Traboulsi T; El Ezzy M; Dumeaux V; Audemard E; Mader S
Oncogene; 2019 Feb; 38(7):1019-1037. PubMed ID: 30190545
[TBL] [Abstract][Full Text] [Related]
37. Discovery of a Novel Class of PROTACs as Potent and Selective Estrogen Receptor α Degraders to Overcome Endocrine-Resistant Breast Cancer
Xie B; Yin Z; Hu Z; Lv J; Du C; Deng X; Huang Y; Li Q; Huang J; Liang K; Zhou HB; Dong C
J Med Chem; 2023 May; 66(10):6631-6651. PubMed ID: 37161783
[TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo molecular imaging of estrogen receptor α and β homo- and heterodimerization: exploration of new modes of receptor regulation.
Paulmurugan R; Tamrazi A; Massoud TF; Katzenellenbogen JA; Gambhir SS
Mol Endocrinol; 2011 Dec; 25(12):2029-40. PubMed ID: 22052998
[TBL] [Abstract][Full Text] [Related]
39. Indole-3-carbinol selectively uncouples expression and activity of estrogen receptor subtypes in human breast cancer cells.
Sundar SN; Kerekatte V; Equinozio CN; Doan VB; Bjeldanes LF; Firestone GL
Mol Endocrinol; 2006 Dec; 20(12):3070-82. PubMed ID: 16901971
[TBL] [Abstract][Full Text] [Related]
40. Estrogen receptor-alpha-interacting cytokeratins potentiate the antiestrogenic activity of fulvestrant.
Long X; Fan M; Nephew KP
Cancer Biol Ther; 2010 Mar; 9(5):389-96. PubMed ID: 20061804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
